BacteriologySusceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest
Introduction
The value of antibiotic sensitivity testing of anaerobes has been questioned in the past owing to the predictable sensitivity to most anti-anaerobe antibiotics, lack of a simple method for testing, and little correlation between clinical treatment outcome with antibiotic susceptibility results Goldstein and Citron 1989, Wexler 1991, Zabransky 1990. Resistance of anaerobic bacteria to antibiotics has, however, been increasing even toward agents with excellent anti-anaerobe activities like metronidazole (Reysset et al. 1993), imipenem (Ueno et al. 1993), and β-lactam/β-lactamase inhibitor combinations (Goldstein et al. 1991). Antibiotic susceptibility testing of anaerobic bacteria is therefore increasingly important.
Traditionally the “gold standard” for anaerobic susceptibility testing has been the broth and agar dilution tests (National Committee for Clinical Laboratory Standards (NCCLS) 1993). They are, however, technically demanding and often too tedious for the routine clinical laboratory. The epsilometer (Etest) enables MIC to be determined in a much simpler way and studies have shown that it is a satisfactory method for MIC determination for most of the common anaerobes encountered clinically Olsson-Liljequist and Nord 1994, Rosenblatt and Gustafson 1995, Wust and Hardegger 1992. Although not generally recommended for anaerobic sensitivity testing (Wexler and Doren 1995), the agar disk diffusion test is an attractive alternative for rapidly growing anaerobes because it is much less expensive than the Etest.
Clostridium difficile is intrinsically resistant to multiple antibiotics, with metronidazole and vancomycin being two of the few antibiotics effective for the treatment of C. difficile associated diarrhea. Because there is no formal recommendation for its susceptibility testing at present, we evaluated the Etest for MIC determination and correlated this with the disk diffusion test.
Section snippets
Materials and method
Results of C. difficile culture and cytotoxin assay performed in the clinical microbiology laboratory of Queen Mary Hospital, Hong Kong, over a 6-month period from September 1996 to February 1997 were analyzed. Stool samples were cultured on cycloserine cefoxitin fructose agar plates supplemented by 5% horse blood (Oxoid, Unipath Ltd., Basingstoke, UK) and incubated in the anaerobic chamber at 37°C for 48 h before reading. Colonies that appeared grayish, opaque, and slightly rhizoid with a
Results
A total of 100 C. difficile isolates were obtained in the 6-month study period. Of the 3112 diarrheal stool samples sent for culture in the same period, 891 (28.6%) yielded a positive culture for enteric pathogens. C. difficile accounted for 11.2% (100/891) of all positive cultures. C. difficile culture was positive in 18.3% (100/546) of the stool samples with a specific request for it. There were 603 requests for C. difficile cytotoxin assay, and 57 (9.5%) of them were positive. Of the 100 C.
Discussion
C. difficile is the commonest cause of nosocomial diarrhea (Gerding et al. 1995), accounting for 15–30% of antibiotic-associated diarrhea without colitis and 90–100% of pseudomembranous colitis associated with antibiotic use (Bartlett 1992). Untreated pseudomembranous colitis carried a mortality rate of 15–30% (Chang 1985), though most other series reported an overall mortality rate of < 1% with appropriate treatment. C. difficile is also an important cause of infective diarrhea in oncology
Acknowledgements
This work was partly supported by a grant from the Committee on Research and Conference Grants.
References (37)
- et al.
Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by C. difficile toxin
Gastroenterology
(1980) - et al.
Evaluation of the Etest for susceptibility testing of anaerobic bacteria
Diagn Microbiol Infect Dis
(1995) - et al.
Clinical significance of alimentary tract microbes in bone marrow transplant recipients
Diagn Microbiol Infect Dis
(1998) Clostridium
- et al.
In vitro synergy studies with C. difficile
Antimicrob Agents Chemother
(1991) - et al.
Multilaboratory evaluation of an agar diffusion susceptibility test for rapidly growing anaerobic bacteria
Rev Infect Dis
(1990) Clostridium difficile-associated diarrhea and colitis
- et al.
Clostridium difficile colitis following treatment with metronidazole and vancomycin
Postgrad Med J
(1987) - et al.
Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to C. difficile
Gut
(1986) - et al.
Antibiotic susceptibility of Clostridium difficile
J Antimicrob Chemother
(1979)
Antibiotic-associated injury to the gut
Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile
Infection
Clostridium difficile colitis associated with cancer chemotherapy
Arch Intern Med
Antibiotic susceptibility testing of anaerobic bacteria by the standardized disc diffusion method with special reference to Bacteroides fragilis
Scand J Infect Dis
Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhoea. A randomized double-blind trial
Arch Intern Med
Antibiotic resistance of Clostridium difficile isolates
Cytobios
Antibiotic sensitivity testing. Report of an international collaborative study
Acta Pathol Microbiol Scand
Antibiotic-associated colitiseffects of antibiotics on Clostridium difficile and the disease in hamsters
Rev Infect Dis
Cited by (98)
Trends in Antimicrobial Resistance Among Enteric Pathogens: A Global Concern. A Global Concern
2016, Antibiotic Resistance: Mechanisms and New Antimicrobial ApproachesAntimicrobial susceptibility of Clostridium difficile isolated from food animals on farms
2016, International Journal of Food MicrobiologyCitation Excerpt :Metronidazole is often administered first as vancomyvin is used primarily in patients who do not respond to metronidazole or experience relapsing CDAD (Kink and Williams, 1998). Typically, isolates of C. difficile are reported as susceptible to these two drugs (Aspevall et al., 2006; Bourgault et al., 2006; Drummond et al., 2003; Jamal et al., 2002; Pituch et al., 2005; Simango, 2006; Simango and Mwakurudza, 2008) although some studies have reported clinical isolates resistant to metronidazole (Bishara et al., 2006; Ferreira et al., 2004; Martin et al., 2008; Wong et al., 1999) or isolates exhibiting reduced susceptibility to vancomycin (Brazier et al., 2001; Pelaez et al., 2005). The first UK isolate of C. difficile with reduced susceptibility to metronidazole was reported in 2001 (Brazier et al., 2001).
Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan
2015, Journal of Infection and ChemotherapyTreatment of Clostridium difficile Infections
2015, Infectious Disease Clinics of North America